Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $959.00M | $814.50M | $805.50M | $794.90M | $687.50M | $572.60M | $627.70M | $622.10M |
| Cost of revenue | $23.20M | $13.80M | $17.60M | $14.00M | $10.30M | $9.20M | $9.30M | $8.00M |
| Gross profit | $935.80M | $800.70M | $787.90M | $780.90M | $677.20M | $563.40M | $618.40M | $614.10M |
| Gross margin | 97.6% | 98.3% | 97.8% | 98.2% | 98.5% | 98.4% | 98.5% | 98.7% |
| Research and development | $326.70M | $296.20M | $258.20M | $250.00M | $244.30M | $263.20M | $185.60M | $195.00M |
| Selling, general and administrative | $439.70M | $318.50M | $301.80M | $291.60M | $286.30M | $276.50M | $287.80M | $234.30M |
| Operating expenses | $784.30M | $635.90M | $577.00M | $541.90M | $531.60M | $539.80M | $476.40M | $430.30M |
| Operating income | $151.50M | $164.80M | $210.90M | $239.00M | $145.60M | $23.60M | $142.00M | $183.80M |
| Operating margin | 15.8% | 20.2% | 26.2% | 30.1% | 21.2% | 4.1% | 22.6% | 29.5% |
| EBITDA | $161.30M | $193.30M | $235.40M | $247.00M | $150.90M | $31.30M | $152.10M | $191.30M |
| Interest income | $12.40M | $28.10M | $25.80M | $22.20M | $20.60M | $21.70M | $22.50M | $23.40M |
| Interest expense | −$2.90M | $0 | $0 | — | $0 | $0 | $0 | — |
| Income before taxes | $162.20M | $246.80M | $239.40M | $291.80M | $159.50M | $14.70M | $162.60M | $190.30M |
| Income taxes | $17.80M | $48.90M | $85.70M | $82.30M | $52.00M | $6.80M | $59.50M | $60.50M |
| Net income | $144.40M | $197.90M | $153.70M | $209.50M | $107.50M | $7.90M | $103.10M | $129.80M |
| Net margin | 15.1% | 24.3% | 19.1% | 26.4% | 15.6% | 1.4% | 16.4% | 20.9% |
| EPS, basic | $1.43 | $1.97 | $1.54 | $2.11 | $1.09 | $0.08 | $1.03 | $1.28 |
| EPS, diluted | $1.39 | $1.91 | $1.48 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 |
| Diluted shares | 104.20M | 103.40M | 104.00M | 102.50M | 101.00M | 102.50M | 103.00M | 104.30M |
Figures describe Neurocrine Biosciences shares, not any token. As of Jul 31, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.